Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-03-19
1991-04-09
Friedman, Stanley J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514418, A01H 4338
Patent
active
050065475
ABSTRACT:
This invention relates to the use of tenidap, 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-1-carboxamide, and the pharmaceutically-acceptable base salts thereof to inhibit the release of elastase by neutrophils in a mammal. This invention also relates to the use of tenidap and its salts for treating elastase-mediated diseases and dysfunctions such as arteritis, proteinuria and pulmonary emphysema in mammals. The methods of this invention comprise administering an effective amount of tenidap or salts thereof to a mammal.
REFERENCES:
patent: 4556672 (1985-12-01), Kadin
patent: 4725616 (1988-02-01), Kadin
patent: 4853409 (1989-08-01), Showell
patent: 4861794 (1989-08-01), Otterness
patent: 4920127 (1990-04-01), King et al.
Janoff, A., American Journal of Pathology 68:579-591 (1972).
Johnson, R. J., et al., J. Exp. Med. 168:1169-1174 (1988).
Showell, H. J., et al., J. Reticuloendothelial Society 30:167-181 (1981).
Showell, H. J., et al., Life Sciences 27:421-426 (1980).
Walenga, R. W., et al., Life Sciences 27:1047-1053 (1980).
Serhan, C. N., et al., Biochem. Biophys. Res. Comm. 107:1006-1012 (1982).
Edelson, H. S., et al., "Dissociation by Piroxicam of Degranulation and Superoxide Anion Generation from Decrements in Chlortetracycline Fluorescence of Activated Human Neutrophils", Biochem. Biophys. Res. Commun. 104:247-253 (1982).
Goldstein, I. M., "Agents that Interfere with Archidonic Acid Metabolism", Inflammation: Basic Principles and Clinical Correlates, Gallin, J. I.
Goldstein, I. M., and Synderman, R., Eds. (1988) pp. 934-946, Raven Press, New York.
Dunn, T. L. et al., "Solid-Phase Radioimmunoassay for Human Neutrophil Elastase: A Sensitive Method for Determining Secreted and Cell-Associated Enzyme", anal. biochem. 150: 18-25 (1985).
Havemann, K. et al., "Physiology and Pathophysiology of Neutral Proteinases of Human Granulocytes", Adv. Exp. Med. Bio. 167:1-20 (1984).
Abramson, et al., "Modes of Action of Aspirin-Like Drugs", P.N.A.S. 82:7227-7231 (1985).
Turner, R. A., et al., "Effects of Benoxaprofen on Human Neutrophil Function", J. Rheumatology 11:265-271 (1984).
Smolen, J. E., et al., "Effects of Indomethacin, 5,8,11,14-Eicosatetraynoic Acid, and p-Bromophenacyl Bromide on Lysosomal Enzyme Release and Superoxide Anion Generation by Human Polymorphonuclear Leukocytes", Biochem. Pharmacol. 29:533-538 (1980).
Mikulikova, D., et al., "The Effect of Indomethacin and Its Ester on Lysosomal Enzyme Release from Polymorphonuclear Leukocytes and Intracellular Levels of GAMP and cGMP after Phagocytosis of Urate Crystals", Biochem. Pharmacol. 31:460-463 (1982).
Maderazo, E. G., et al., "Inhibition of Human Polymorphonuclear Leukocyte Cell Responses by Ibuprofen", J. Pharmaceutical Sciences 73:1403-1406 (1984).
CA: 110(21) 185555v.
CA: 110(25) 229951y.
Benson Gregg C.
Criares T.
Friedman Stanley J.
Lumb J. Trevor
Pfizer Inc.
LandOfFree
Tenidap as an inhibitor of the release of elastase by neutrophil does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tenidap as an inhibitor of the release of elastase by neutrophil, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tenidap as an inhibitor of the release of elastase by neutrophil will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2034765